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1. Introduction 
Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of 
morphologically mature, but immuno-incompetent B-lymphocytes in the bone marrow, 
peripheral blood, spleen and lymphoid organs. With an annual incidence of about 2-3/ 
100000 in the general population (Hamblin, 2009), CLL represents a frequent leukemia 
type. Since CLL mostly affects persons of advanced age, the incidence among persons 
above 65 years reaches ten times this frequency (Eichhorst et al., 2009). Moreover CLL 
follows a remarkably heterogeneous course, emphasizing the need for personalized 
treatment approaches. Despite recent advances in CLL therapy, the disease still remains 
incurable and new treatment options need to be developed (Hallek et al., 2008). New 
insights into CLL biology have started to result in new targeted, sometimes patient 
group-specific treatment approaches (Pleyer et al., 2009; Zenz et al., 2010). Candidate 
substances for pre-clincial assays are mostly molecularly targeted drugs, i.e. either small 
molecules interfering with intracellular signaling (Wickremasinghe et al., 2011) or 
mononoclonal antibodies (Jaglowski et al., 2010). As examples we will discuss in this 
chapter the pre-clinical assessment of protein and lipid kinase inhibitors and of 
monoclonal antibodies. 
Since candidate substances with a potential for treating CLL become available at an 
increasing pace, there is a growing need for comprehensive laboratory assessment of these 
substances. For this purpose the effects of these drug candidates on fresh CLL 
lymphocytes are compared by means of viability and cytotoxicity assays with the aim of 
selecting suitable candidates for further development. In addition viability and 
cytotoxicity assays on CLL cells serve to prepare candidate substances for clinical trials 
and to determine, which subgroups of patients respond best, in the sense of personalized 
medicine. This endeavor constitutes the small excerpt of the drug discovery process 
immediately preceding clinical trials (Collins & Workman, 2006). Since it links laboratory 
investigation and clinical application it can be understood as translational research, which 
is further underscored by patient samples being subjected to cultivation and observation 
in the laboratory. 
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B lymphocytes freshly isolated from peripheral blood of CLL patients constitute a readily 
available source for the pre-clinical in vitro assessment of drugs and combinations with 
therapeutic potential for treating CLL. Due to the epidemiological features of CLL as a 
frequent chronic leukemia, with many patients living with the disease for extended periods, 
a continuous supply of blood samples can be made available and used in a meaningful 
manner by performing pre-clinical assays, which, according to the concept of translational 
medicine, in turn could lead to improved therapies. Drug assessment on fresh CLL samples 
can be performed rapidly and relatively conveniently by comparing untreated and treated 
in vitro cultures.  
On the other hand, primary cultures of B cells freshly isolated from the peripheral blood of 
CLL patients often may represent an insufficient model for predicting clinical drug efficacy, 
since they are known to behave differently from CLL lymphocytes in their in vivo 
environment.  This is evident from the obviously contrasting behavior of CLL cells in vivo 
and during in vitro culture. Whereas accumulation of CLL cells in vivo is thought to occur 
due to resistance towards apoptosis and a certain degree of cell proliferation, in vitro 
cultures spontaneously undergo apoptosis and show low viability and almost completely 
absent proliferation. Because this contrasting behaviour of CLL cells in vitro and in vivo can 
be attributed to a lack of the appropriate micro-environment during laboratory culture, the 
value of drug assessment on CLL lymphocytes ex vivo can be greatly enhanced by 
mimicking certain micro-environmental stimuli. 
Commonly used cytotoxicity and viability assays are compiled in this chapter and will be 
discussed in the context of the assessment of potential anti-CLL drugs. On the level of 
individual susceptibility it is well established for chemotherapeutic agents that sensitivity of 
tumor cells in vitro corresponds to the probability of clinical response (Bosanquet et al., 
2009). Therefore one would expect also for targeted drugs that in vitro assays enable to some 
degree the comparison of the efficacies of different agents and the prediction of the response 
of molecularly defined subgroups of CLL patients. As examples for correlations of 
molecularly defined patient subgroups with treatment susceptibility in vitro we name here 
the clearly higher dasatinib sensitivity of CLL samples with unmutated IgHV genes as 
compared to mutated ones (Veldurthy et al., 2008) or the correlation of the B cell depletion 
induced by CD20 antibodies with antigen expression on the surface of CLL cells (Patz et al., 
2011). 
In this chapter we review the pros and cons of pre-clinical drug assessment in comparatively 
simple ex vivo assays. The predictability of treatment out-come from in vitro cultures of CLL 
lymphocytes must be considered, since there are known limitations of the assay system, 
which can, however, be overcome to a certain degree by linking the results to investigations 
of target and cell type specificity.   
2. Performing cytotoxicity assays on CLL samples 
In the course of the pre-clinical assessment of anti-CLL drug candidates, in vitro cultures of 
CLL lymphocytes are treated with test substances. Subsequently dose-dependent treatment 
effects on the viability of CLL cells are recorded by means of established proliferation and 
cytotoxicity assays. These assays yield a first measure of drug potency for CLL lymphocytes, 
but certainly need to be rigidly controlled and standardized. Moreover they should be 
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accompanied by biochemical assays in order to assure cell type and target specificity. Such 
comprehensive approaches will allow the design of meaningful drug combinations, which 
then are to be subjected to another round of in vitro sensitivity assays. 
Cytotoxicity assays play a pivotal role in pre-clinical drug testing (Kepp et al., 2011) and 
many of them are suitable for assessing treatment effects on fresh CLL cells (Table 1). Some 
of these assays are based on absolute cell counts or less laborious surrogate parameters 
determining total cellular activities e.g. in colorimetric or fluorimetric non-clonogenic 
microculture assays (Lindhagen et al., 2008). In contrast, flow cytometric assays usually 
yield percentages of cells with certain properties within the investigated cell population 
unless they are standardized for the examined volume, e.g. by absolute counting beads.  
 
Method Technological platform parameters 
cell counting light microscope trypan blue exclusion 
metabolic activity absorbance reader tetrazolium salt reduction 
ATP consumption luminometer luciferase activity 
intracellular esterase 
activity 
fluorimeter 
conversion of non-fluorescent 
fluorescein diacetate 
DNA replication 
absorbance reader 
flow cytometry 
bromo-deoxyuridine 
incorporation 
phosphatidylserine 
exposure 
flow cytometry annexin V-binding 
membrane disintegration flow cytometry 
staining with DNA intercalating 
dye 
Δψm dissipation flow cytometry fluorescent dye, e.g. DiOC6 
morphology flow cytometry forward scatter / side scatter 
production of reactive 
oxygen species 
flow cytometry 
fluorigenic substrate, 
e.g. CM-H2-DCF-DA 
caspase activation 
flow cytometry 
immunoblotting 
fluorescent substrates 
detection of cleaved fragments 
Table 1. Selected cytotoxicity and viability assays commonly used with CLL samples. 
2.1 Flow cytometric cell death and viability assays 
Flow cytometric assessment of phosphatidylserine exposure and membrane disintegration 
is among the viability and cytotoxicity assays most frequently applied for monitoring drug 
effects on CLL cells. Percentages of cell populations undergoing cell death can be 
determined by monitoring the loss of membrane asymmetry in early phases of apoptosis 
and subsequent membrane disruption (Fig. 1). This can be achieved by staining cells, e.g. B 
lymphocytes, with fluorescently labeled annexin V, which binds to phosphatidylserine with 
high affinity (Koopman et al., 1994). Phosphatidylserine exposure accompanies early phases 
of apoptosis, before membrane disintegration of the cytoplasma membrane allows access of 
DNA intercalating dies to the nucleus. Counter-staining with DNA intercalating dyes 
originally served the distinction of apoptotic from necrotic cells. Analysis of annexin V 
binding or DNA staining can be replaced for staining with dyes indicating mitochondrial 
membrane potential, e.g. 3,3’-dihexyloxacarbocyanine iodide (DiOC6) (Stanglmaier et al., 
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2004; Veldurthy et al., 2008), or reactive oxygen species, e.g. the fluorogenic chloromethyl-
2,7-dichlorodihydrofluorescein-diacetate (CM-H2-DCF-DA) (Lilienthal et al., 2011). Usually 
populations of CLL cells with phosphatidylserine exposure coincide with those showing 
typical morphological signs of apoptosis, i.e. reduced size and increased granularity as 
indicated by forward-scatter (FSC) and side-scatter (SSC) in the flow cytometer. Concerns 
have been raised about a possible over-estimation of drug effects due to flow cytometry 
artefacts. For instance, the widely used determination of phosphatidylserine exposure was 
claimed to over-estimate apoptosis induction in the extraordinarily fragile CLL cells due to 
in vitro handling during sample preparation for flow cytometry (Groves et al., 2009). 
Similarly antibody effects on CLL samples determined by flow cytometry were suspected of 
being misinterpreted owing to cell aggregation (Golay et al., 2010). These concerns can be 
overcome by parallel biological effect monitoring in several different assay systems as 
controls. 
 
FITC-
annexin V-
conjugate
apoptosis
phosphatidylserine exposure
DNA-intercalating dye,
e.g. 7-amino-actinomycin D
(7-AAD)
annexin V-binding
staining of nuclear DNA
in non-viable cells
cytoplasm cytoplasm
O O
OO
OO
C C
CH3 CH3
NH2
NH2
N
ThrThr D-ValD-Val
MeVal MeValProPro
Sar Sar
membrane disintegration
A
B
 
 
Fig. 1. Principle of a widely used assay for the determination of the percentages of apoptotic 
cells. The flow cytometric assessment of phosphatidylserine exposure (A) and membrane 
disintegration (B) can be performed simultaneously.  
Part (A) adapted from Zhang et al., 1997 and Pharmingen, 1998. 
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2.2 Concentration dependence 
Investigation of the dose-dependency of drug effects is an important confirmation of any 
observations that by far surpasses the importance of repeated measurements. In addition, 
the shape of dose response curves sometimes can provide mechanistic clues, e.g. in the case 
of saturation effects. When drugs are investigated for CLL that previously have been pre-
clinically developed or admitted for the treatment of other cancers, it is possible to consider 
achievable plasma concentrations for the in vitro assessment. Biological effect measurements 
obtained at multiple concentrations can be conveniently summarized by concentrations 
inhibiting 50 % (IC50). These IC50 concentrations can be a useful manner of comparing the 
effects of different drugs or diverging sensitivities of different samples. In the case of 
saturation effects, as in the dose response of CLL lymphocytes to dasatinib (Veldurthy et al., 
2008), it might be more appropriate to indicate the individual saturation levels of response 
rather than extrapolating IC50 concentrations. Moreover, investigators must not be misled by 
the convenience of such tabulated values to regard them as sample-specific constants and 
therefore to apply them to different assay types, since IC50 concentrations strictly depend on 
the type of assay performed (Krause & Hallek, 2011). 
3. Mimicking micro-environmental interactions 
Considering the micro-environment of CLL cells may improve predictions of clinical drug 
efficacy from in vitro assays on fresh CLL samples. Regarding their resistance to apoptosis 
CLL cells in culture behave entirely differently from the situation in vivo, owing to 
dependence on their micro-environment. Therefore it is necessary to simulate certain micro-
environmental stimuli for drug assessment in vitro, for instance following the approaches 
described in the following subchapters. A number of ligand/receptor pairs have been 
identified that activate CLL cells (Fig. 2) (Munk Pedersen & Reed, 2004), among them the 
chemokine stroma-derived factor 1, nowadays referred to as CXCL12 and its receptor 
CXCR4 on CLL cells, that belongs to the class of G-protein-coupled 7-transmembrane 
domain receptors (Burger & Kipps, 2006) and VCAM-1 (CD106) expressed on the surface of 
stroma cells that interacts with the integrin VAL-4 (CD49a) on CLL cells (Burger et al., 2009). 
The strict dependence of CLL cells on the interactions with their environment is also 
apparent from the absence of good cell line models for CLL. 
3.1 B cell receptor stimulation 
Like for normal lymphocytes, also the fate of CLL cells is to a high degree determined by B 
cell receptor (BCR) stimulation (Stevenson & Caligaris-Cappio, 2004). According to the 
degree of somatic hypermutation in rearranged antigen receptor genes, subgroups of CLL 
clones with immunoglobulin heavy chain variable region (IgHV) genes can be distinguished 
that reflect progressing B cell development stages corresponding to naïve or memory B cells. 
Usually the threshold separating these molecularly defined prognostic subgroups is set at 2 
% sequence divergence of rearranged IgHV genes from the closest germline sequences. The 
CLL subgroups with unmutated or mutated IgHV genes have a widely different prognosis 
indicated by 24 versus 8 years median overall survival after diagnosis (Hamblin et al., 1999). 
High expression of zeta-assoziated protein 70 (ZAP-70) and of CD38 serve as surrogate 
markers of unmutated IgHV genes (Crespo et al., 2003; Hamblin et al., 2002). 
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Antigen contact for CLL cells can be mimicked in vitro by crosslinking surface IgM by means 
of anti-IgM antibodies. Long lasting stimulation of the BCR leads to prolonged survival of 
CLL cells (Deglesne et al., 2006). This can be achieved by using soluble anti-IgM or anti-IgM-
coated surfaces.  
3.2 CD40 stimulation 
The CD40 molecule expressed on the surface of CLL cells belongs to the tumor necrosis 
factor family and participates in antigen recognition as a co-receptor.  Its cognate ligand, 
CD40 ligand (CD40L), also known as CD154, is expressed on the surface of activated T 
lymphocytes. Engagement of CD40 on CLL lymphocytes mimics the micro-environment 
inside lymph nodes and leads to protection against DNA damaging substances, e.g. 
chemotherapeutic agents. CD40L stimulation of CLL cells can be provided by co-culture 
with fibroblasts expressing recombinant CD154. For instance co-culture with CD40L 
expressing fibroblasts protects CLL cells from DNA damaging agents, but this effect can be 
partly reversed by the kinase inhibitor dasatinib (Hallaert et al., 2008). The sensitivity of CLL 
cells for the Bcl-2 antagonist ABT737 is decreased by a factor of 1000, if the CLL cells are co-
cultivated with fibroblasts expressing CD40L (Vogler et al., 2009). 
3.3 Stroma cell-derived soluble factors and cell surface interactions 
The soluble factors produced by bone marrow stromal cells include the chemokine 
CXCL12, which despite its original designation as stroma-cell derived factor is shown in 
Fig. 2 as a micro-environmental factor occurring in peripheral blood, owing to its alternate 
origin from nurse-like cells. Stimulation by purified recombinant CXCL12 induced the raf-
dependent mitogen activated protein (MAP) kinase cascades in CLL cells, which 
augmented their survival and was targeted by the raf inhibitor sorafenib (Messmer et al., 
2011).  
In vivo, inhibition of apoptosis may occur preferentially in pseudofollicles containing CLL 
and accessory cells, due to cell contact and mutual paracrine and autocrine stimulation. In 
vitro, co-culture with bone-marrow-derived stromal cells, e.g. the cell line HS-5, may 
provide stimuli for long-term survival of CLL cells.  In co-cultures of primary CLL cells with 
HS-5 cells, various chemokines attracting T lymphocytes, most prominently CCL4 and 
CCL3, were detected, which are not produced by HS-5 control cultures (Seiffert et al., 2010). 
The proteins found in the supernatant of HS-5 co-cultures included factors, which are 
commonly secreted by monocytes, e.g. soluble CD14. Among the soluble factors provided to 
CLL cells by co-culture with the bone marrow stromal cell line HS5, vascular endothelial 
growth factor (VEGF) is partly responsible for the increase in viability of co-cultivated CLL 
cells (Gehrke et al., 2011). 
3.4 Oligonucleotides containing CpG dinucleotides 
Toll like receptor 9 (TLR9) has been identified as a part of the innate immune response 
recognizing unmethylated foreign DNA that can be mimicked by phosphothioate 
oligodeoxynucleotides containing CpG dinucleotides (CpG-ODN) (Krieg, 2006). Survival 
and proliferation of CLL cells can be considerably enhanced by class B CpG-ODN, e.g. 
DSPN-30 (Decker et al., 2000). Like CD40 ligation, activation of CLL cells through TLR9 
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occupation by CpG-ODN was exploited as a mitogenic signal in order to obtain 
metaphase chromosomes for cytogenetic analysis by fluorescent in situ hybridization 
(Mayr et al., 2006). The importance of activated CLL cells in drug assessment is 
demonstrated by the example of mTOR inhibitors. In untreated CLL cells rapamycin 
showed an IC50 of 10 µM for apoptosis induction (Aleskog et al., 2008). In contrast less 
than one thousandth of this concentration of RAD001 or 10 nM rapamycin was sufficient 
for complete inhibition of the cell proliferation induced by CpG-ODN (Decker et al., 
2003).  
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Fig. 2. Microenvironment interactions of CLL cells. The survival of CLL lymphocytes can be 
prolonged by contact with different accessory cells in the peripheral blood, lymphoid 
system and bone marrow.  Some prominent interactions of CLL cells with soluble factors 
and cell surface molecules supplied by accessory cells are shown. On the surface of CLL 
cells receptors for various soluble factors are expressed, e.g. for the chemokine CXCL12, 
formerly designated as stroma-derived factor 1 (SDF-1), for the cytokine interleukin-4 (IL-4), 
and for vascular endothelial growth factor (VEGF). CD40 or the integrin VAL-4 on the 
surface of CLL cells interact with CD40 ligand (CD40L) on T cells or VCAM-1 on follicular 
dendritic cells and other stromal cells, respectively. Adapted from Munk Pedersen et al., 
2004. 
In addition to activating CLL cells CpG-ODN were found to increase surface expression 
levels of co-stimulatory molecules including CD20 (Jahrsdorfer et al., 2001). Consequently, 
the same CpG-ODN DSPN-30 that is commonly used for activating CLL cells, increased 
CD20 expression on freshly isolated CLL cells, which in turn led to higher B cell depletion 
by the type II CD20 antibody GA101 (Patz et al., 2011). 
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3.5 B cell depletion from whole blood samples 
Monoclonal antibodies (MABs) induce direct cell death (DCD) of tumor cells via signal 
transduction and additional Fc-mediated cytotoxic effects, namely antibody-dependent 
cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) (Fig. 
3). In order to include ADCC and CDC in measurements of overall MAB effects, the 
extent of tumor cell depletion by MABs from individual blood samples can be 
determined by multi-color flow cytometry comparing treated and untreated whole blood 
cultures.  
CLL
lymphocyte
NK
cell
macrophage
M
AC
DCD
CDC
ADCC
C3
C3b
FcγR / CR mediated
phagocytosis or ADCC
FcγR
CR
antigen
antibody
 
Fig. 3. Killing mechanisms of monoclonal antibodies and their assessment. Apart from direct 
cell death (DCD) induction in tumor cells, monoclonal antibodies exert their action via Fc-
mediated functions, namely complement-mediated cytotoxicity (CDC) and antibody-
dependent cell-mediated cytotoxicity (ADCC) and phagocytosis. Due to the importance of 
CD20 antibodies in CLL therapy, a structure crossing the cell membrane four times is shown 
as the surface antigen on CLL cells. This overall structural organization is shared by another 
emerging target for immunotherapy, the tetraspanin CD37. Ways to examine the above 
mechanisms on isolated CLL cells and whole blood samples are compiled in Table 2 and 
described in the text. Adapted from Olszewski & Grossbard, 2004 and Jaglowski et al., 2010. 
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4. Pre-clinical assessment of kinase inhibitors 
Prototypic targeted therapy by the tyrosine kinase inhibitor imatinib was developed for Bcr-
Abl positive leukemias, in which deregulated Abl activity is a predominant driving force 
(Druker et al., 2001). In contrast, the pathogenesis of CLL appears to be multi-factorial. The 
second generation of Abl inhibitors for treatment of imatinib-resistant Bcr-Abl positive 
leukemias achieves greater efficacy against mutant forms of the Abl kinase (Weisberg et al., 
2007). Some of these inhibitors, e.g. dasatinib (Shah et al., 2004) and bosutinib (Puttini et al., 
2006) are dual-specific and target Abl and additionally Src kinases. Since members of the 
latter tyrosine kinase family, e.g. Lyn (Contri et al., 2005) and Lck (Majolini et al., 1999) have 
been suggested to be involved in CLL pathogenesis, we conducted an assessment of 
dasatinib on CLL cells (Veldurthy et al., 2008). This pre-clinical investigation indicated an 
influence of Src kinase inhibition on the cellular survival of CLL cells with preference for the 
subgroups with unmutated immunoglobulin heavy chain genes or with high ZAP70 
expression and thus indicated patient groups that might profit most from Src kinase 
inhibition. Since the fate of CLL B lymphocytes critically depends on BCR signaling 
(Stevenson & Caligaris-Cappio, 2004), inhibition by kinase inhibitors of survival pathways 
emanating from the BCR or from micro-environmental stimuli (Burger et al., 2009) 
represents a promising strategy for treating CLL (Gandhi, 2010). 
Drug assessment on primary CLL cells serves as preparation for clinical trials and to some 
degree enables comparison of the efficacies of different agents and the prediction of the 
response of molecularly defined subgroups of CLL patients. The clearly higher dasatinib 
sensitivity of CLL samples with unmutated IgVH genes as compared to mutated ones is an 
example for this type of correlation (Veldurthy et al., 2008). Signaling analysis revealed that 
treatment of primary CLL cells with dasatinib drastically reduces the level of activated SFK in 
CLL cells, but inhibits downstream BCR signaling pathways and induces apoptosis more 
strongly in the patient subgroup with aggressive disease. The extent of dasatinib-induced 
apoptosis in CLL cells corresponds to the concomitant decrease in the phosphorylation of the 
direct SFK substrates Syk and phospholipase C-γ (Song et al., 2010). Signaling analysis during 
SFK inhibition thus contributed to the rationale for pre-clinical assessment of Syk inhibitors on 
CLL cells (Baudot et al., 2009; Buchner et al., 2009). For another second generation dual 
Abl/Src inhibitor, bosutinib, inhibition of the receptor tyrosine kinase Axl was found to be 
partially responsible for its apoptosis induction in CLL cells (Ghosh et al., 2010). 
Inhibition of Abl does not reduce viability of CLL cells on its own, but can sensitize CLL 
cells for chemotherapeutic agents, e.g. chlorambucil, by interfering with DNA repair (Aloyz 
et al., 2004). Inhibitors of the delta isoform of the catalytic p110 subunit of 
phosphatidylinositol-3-kinase (PI3K) show moderate efficiencies on primary CLL 
lymphocytes without activation that contrast the promising effects in clinical trials. The 
observed pre-clinical efficiency of the PI3K-delta inhibitor CAL-101 is not abrogated by 
micro-environmental stimulation and other cell types, while other cell types, e.g. natural 
killer cells are not influenced by CAL-101 (Herman et al., 2010). 
5. Pre-clinical assessment of monoclonal antibodies 
Apart from small molecules, monoclonal antibodies constitute another group of targeted 
therapeutics for the treatment of CLL. This group includes the first biological anti-tumor 
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agent, namely the CD20 antibody rituximab. As a common cell surface antigen of all B cells 
except stem or plasma cells, CD20 has become a very effective antibody target for the 
treatment of B cell malignancies (Molina, 2008) including CLL despite variable surface 
expression on CLL cells. Together with the monoclonal anti-CD52 antibody alemtuzumab, 
rituximab thus may be counted among the most efficient targeted treatment options for CLL 
achieved so far. In a recent phase III trial inclusion of rituximab was shown to substantially 
improve the established fludarabine / cyclophosphamide chemotherapy regimen (Hallek et 
al., 2010). 
Apart from DCD induction in tumor cells, monoclonal antibodies exert their action via Fc-
mediated functions, namely CDC, ADCC and phagocytosis (Jaglowski et al., 2010; 
Olszewski & Grossbard, 2004) (Fig. 3). Therefore an assessment of antibody effects on CLL 
cells ex vivo can either be performed on freshly isolated CLL cells in separate dedicated 
assays for each mentioned mechanisms, or in a comprehensive assay from whole (Table 2). 
For assessing antibody effects on isolated CLL cells, the same procedures as for other anti-
CLL agents can only be applied for the determination of DCD. For instance DCD induction 
by rituximab in freshly isolated CLL cells was assessed according to viable cell counts, 
metabolic activity and phosphatidylserine exposure and was found variable among 
individual samples and considerably smaller than in lymphoma cell lines (Patz et al., 2011; 
Stanglmaier et al., 2004). Since DCD induction in primary CLL cells may constitute only a 
minor fraction of overall B cell depletion as in the case of rituximab (Voso et al., 2002), it is 
indispensable to additionally assess Fc-mediated mechanisms. For performing ADCC assays 
on isolated CLL lymphocytes, effector cells need to be externally added, e.g. autologous or 
heterologous peripheral blood mononuclear cells or a natural killer cell line (Weitzman et 
al., 2009). Similarly, CDC can be assessed by monitoring changes in the membrane integrity 
of CLL cells after incubation in medium containing high concentrations of complete as 
compared to heat-inactivated serum  (Golay et al., 2000; Patz et al., 2011).  
 
Mechanism Isolated CLL cells Whole blood 
DCD Cytotoxicity or viability assays 
Requires distinction of CLL 
lymphocytes from other cell 
populations  
CDC 
Comparison of effects with 
complete or heat-inactivated 
serum 
Complement inhibition by cobra 
venom factor 
ADCC Externally added effector cells Blocking antibodies for Fc receptors 
Table 2. Determination and dissection of different mechanisms of antibody-induced 
cytotoxicity. 
As an alternative to these separate assays, we applied a B cell depletion assay from whole 
blood encompassing Fc-mediated antibody-induced cytotoxicity. This assay is based on the 
enumeration of B lymphocytes in differentially treated whole blood samples after staining 
the general, B- and T- lymphocyte antigens CD45, CD19 and CD3 using three color flow 
cytometry and commercially available fluorescently labeled immunoreagents. B cell 
depletion can be calculated from the B cell counts in antibody-treated versus untreated 
control samples. B/T cell ratios with the T cell population as an internal standard can be 
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used for this calculation, if T cell counts are proven to be unaffected by the antibody 
treatment. Alternatively absolute B cell counts can be determined using externally added 
fluorescent counting beads. In part the contributions of DCD, CDC and ADCC to the 
observed B cell depletion from whole blood samples can be dissected. Thus, we were able to 
show a substantial contribution of ADCC to the B cell depletion by the novel type II CD20 
antibody GA101 (Moessner et al., 2010) by blocking the interaction of FcγIIIa on NK cells 
and macrophages and the Fc exposed on antibody-coated target cells by incubation with 
anti-CD16 antibody in whole blood from healthy donors but not CLL patients (Patz et al., 
2011).   In summary, flow cytometric determination of B cell depletion from whole blood has 
the potential of comparing antibody effects on individual CLL samples and of predicting 
clinical responses.  
Resistance mechanisms to anti-CLL antibodies have been unraveled by pre-clinical models 
and some of the influences interfering with antibody efficacy may be recapitulated in the the 
present B cell depletion from whole blood samples (Table 3) (Reslan et al., 2009).  Thus the 
shape of the dose response curves of GA101 or mAb37.1 observed in the B cell depletion 
assay (Krause et al., 2011; Patz et al., 2011) is of saturation type and suggests an influence on 
antibody effects of individually different levels of endogenous human IgG in the assay 
matrix (Preithner et al., 2006). Similarly, varying ratios of effector to target cells, the 
Phe158Val polymorphism of FcγIIIa (Cartron et al., 2002) as well as complement depletion 
(Kennedy et al., 2004) will influence B cell depletion from whole blood samples. Thus, the 
assay described here has the advantage of reflecting both, the efficiency of antibody-induced 
B cell depletion and the potential to supply host-dependent immune functions and thus 
should be able to predict at the individual level the clinical efficiency of therapeutics 
assayed in vitro.  
 
Influence References 
Antigen density on target cells Golay et al., 2001, Patz et al., 2011 
Complement depletion Kennedy et al., 2004 
Complement inhihibitors CD59 and CD55 Golay et al., 2001 
Ratio of effector to target cells  
Plasma levels of IgG Preithner et al., 2006 
Fc receptor polymorphisms Cartron et al., 2002 
Table 3. Influences on antibody efficacy in a whole blood matrix. 
6. Conclusions 
Due to the dependence of CLL lymphocytes on their micro-environment, the predictive 
value of simple cytotoxicity assays on freshly isolated CLL cells can be enhanced by 
activating CLL cells using procedures that mimic certain micro-environmental stimuli. In 
the case of monoclonal antibodies, effector cells and complement system need to be 
included in order to comprise indirect antibody-mediated mechanisms. For arriving at valid 
predictions, results of the individualized in vitro sensitivity testing should be linked to 
mechanistic and biochemical target validation studies, ideally involving genetically defined 
systems. Remarkably three major topics addressed in this chapter, namely the importance of 
accompanying signaling analysis, consideration of the micro-environment of CLL cells and 
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combination with chemotherapeutic agents conceptually strongly overlap with general 
targeting strategies in contemporary pre-clinical anticancer drug discovery (Caponigro & 
Sellers, 2011).   
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